Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • steroid-refractory
Cyclosporin Therapy: A Promising Rescue Treatment for Severe Steroid-Refractory Ulcerative Colitis
Posted inGastroenterology Specialties

Cyclosporin Therapy: A Promising Rescue Treatment for Severe Steroid-Refractory Ulcerative Colitis

Posted by MedXY By MedXY 08/17/2025
Cyclosporin demonstrated high clinical response rates in adults with severe steroid-refractory ulcerative colitis, allowing over half to avoid colectomy and highlighting its role as an effective rescue therapy.
Read More
Ruxolitinib Offers Durable Clinical Benefit in Steroid-Refractory Chronic Graft-Versus-Host Disease: Three-Year Final Results of the REACH3 Trial
Posted inClinical Updates news Specialties Transplantation

Ruxolitinib Offers Durable Clinical Benefit in Steroid-Refractory Chronic Graft-Versus-Host Disease: Three-Year Final Results of the REACH3 Trial

Posted by MedXY By MedXY 08/07/2025
The REACH3 study confirms ruxolitinib's superiority over best available therapy in steroid-refractory/dependent chronic GVHD, demonstrating sustained efficacy, improved failure-free survival, and a manageable long-term safety profile over three years.
Read More
  • The 400 Percent Transit Penalty: How Travel Barriers Systemically Restrict Methadone Access
  • Post-Dobbs Abortion Bans Linked to Significant Rise in Postpartum Depression Among Low-Socioeconomic Populations
  • RSV-Related Hospitalization Linked to Surge in Acute Myocardial Infarction and Stroke Risk
  • Beyond the Incessant Ovulation Hypothesis: How Menopausal Status and Birth Cohort Reshape Ovarian Cancer Risk
  • Blended Delivery of Parenting Programs in Primary Care Enhances Child Development: A Randomized Clinical Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in